Similar articles for PMID: 35489750

Year	Number of Results
2002	1
2004	1
2006	1
2007	1
2008	2
2009	2
2010	4
2011	3
2012	8
2013	4
2014	6
2015	8
2016	10
2017	15
2018	10
2019	10
2020	14
2021	12
2022	32
2023	11
2024	0

1

Proton Pump Inhibitors Ameliorate Capecitabine-induced Hand-Foot Syndrome in Patients With Breast Cancer: A Retrospective Study.

Takemura M, Ikemura K, Yoshinami T, Toyozumi Y, Shintani T, Ueda M, Shimazu K, Okuda M. Takemura M, et al. Anticancer Res. 2022 May;42(5):2591-2598. doi: 10.21873/anticanres.15737. Anticancer Res. 2022. PMID: 35489750

2

Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome.

Hiromoto S, Kawashiri T, Yamanaka N, Kobayashi D, Mine K, Inoue M, Uchida M, Shimazoe T. Hiromoto S, et al. Sci Rep. 2021 Apr 26;11(1):8964. doi: 10.1038/s41598-021-88460-9. Sci Rep. 2021. PMID: 33903667 Free PMC article.

3

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial.

Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang YJ, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V, King K, Koski S, Mulder K, Hiller JP, Scarfe A, Spratlin J, Huang YJ, Khan-Wasti S, Chua N, Sawyer MB. Chu MP, et al. JAMA Oncol. 2017 Jun 1;3(6):767-773. doi: 10.1001/jamaoncol.2016.3358. JAMA Oncol. 2017. PMID: 27737436 Free PMC article. Clinical Trial.

4

Predictors of Hand-Foot Syndrome and Pyridoxine for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized Clinical Trial.

Yap YS, Kwok LL, Syn N, Chay WY, Chia JWK, Tham CK, Wong NS, Lo SK, Dent RA, Tan S, Mok ZY, Koh KX, Toh HC, Koo WH, Loh M, Ng RCH, Choo SP, Soong RCT. Yap YS, et al. JAMA Oncol. 2017 Nov 1;3(11):1538-1545. doi: 10.1001/jamaoncol.2017.1269. JAMA Oncol. 2017. PMID: 28715540 Free PMC article. Clinical Trial.

5

Study protocol of a single-arm phase 2 study evaluating the preventive effect of topical hydrocortisone for capecitabine-induced hand-foot syndrome in colorectal cancer patients receiving adjuvant chemotherapy with capecitabine plus oxaliplatin (T-CRACC study).

Iimura Y, Furukawa N, Ishibashi M, Ahiko Y, Tanabe T, Aikou S, Shida D, Nojima M, Kuroda S, Boku N. Iimura Y, et al. BMC Gastroenterol. 2022 Jul 14;22(1):341. doi: 10.1186/s12876-022-02411-w. BMC Gastroenterol. 2022. PMID: 35836104 Free PMC article.

6

Polymorphisms of MTHFR and TYMS predict capecitabine-induced hand-foot syndrome in patients with metastatic breast cancer.

Lin S, Yue J, Guan X, Yuan P, Wang J, Luo Y, Fan Y, Cai R, Li Q, Chen S, Zhang P, Li Q, Ma F, Xu B. Lin S, et al. Cancer Commun (Lond). 2019 Oct 11;39(1):57. doi: 10.1186/s40880-019-0399-z. Cancer Commun (Lond). 2019. PMID: 31601265 Free PMC article.

7

Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

Zielinski C, Lang I, Beslija S, Kahan Z, Inbar MJ, Stemmer SM, Anghel R, Vrbanec D, Messinger D, Brodowicz T. Zielinski C, et al. Br J Cancer. 2016 Jan 19;114(2):163-70. doi: 10.1038/bjc.2015.419. Epub 2015 Dec 10. Br J Cancer. 2016. PMID: 26657657 Free PMC article. Clinical Trial.

8

Randomized double-blind, placebo-controlled study of topical diclofenac in the prevention of hand-foot syndrome in patients receiving capecitabine (the D-TORCH study).

Santhosh A, Kumar A, Pramanik R, Gogia A, Prasad CP, Gupta I, Gupta N, Cheung WY, Pandey RM, Sharma A, Batra A. Santhosh A, et al. Trials. 2022 May 19;23(1):420. doi: 10.1186/s13063-022-06353-2. Trials. 2022. PMID: 35590388 Free PMC article. Clinical Trial.

9

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.

Pandy JGP, Franco PIG, Li RK. Pandy JGP, et al. Support Care Cancer. 2022 Nov;30(11):8655-8666. doi: 10.1007/s00520-022-07175-3. Epub 2022 Jun 2. Support Care Cancer. 2022. PMID: 35655045 Review.

10

Significant association between hand-foot syndrome and efficacy of capecitabine in patients with metastatic breast cancer.

Azuma Y, Hata K, Sai K, Udagawa R, Hirakawa A, Tohkin M, Ryushima Y, Makino Y, Yokote N, Morikawa N, Fujiwara Y, Saito Y, Yamamoto H. Azuma Y, et al. Biol Pharm Bull. 2012;35(5):717-24. doi: 10.1248/bpb.35.717. Biol Pharm Bull. 2012. PMID: 22687407 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

132 results

Results by year